The estimated Net Worth of Bradley Sitko is at least $152 Tausend dollars as of 2 October 2023. Bradley Sitko owns over 1,750 units of XOMA Royalty stock worth over $151,872 and over the last 2 years Bradley sold XOMA stock worth over $0.
Bradley has made over 6 trades of the XOMA Royalty stock since 2023, according to the Form 4 filled with the SEC. Most recently Bradley bought 1,750 units of XOMA stock worth $24,850 on 2 October 2023.
The largest trade Bradley's ever made was buying 3,500 units of XOMA Royalty stock on 12 May 2023 worth over $73,080. On average, Bradley trades about 1,300 units every 20 days since 2023. As of 2 October 2023 Bradley still owns at least 5,600 units of XOMA Royalty stock.
You can see the complete history of Bradley Sitko stock trades at the bottom of the page.
Bradley's mailing address filed with the SEC is C/O XOMA CORPORATION, 2200 POWELL STREET, SUITE 310, EMERYVILLE, CA, 94608.
Over the last 21 years, insiders at XOMA Royalty have traded over $74,428,857 worth of XOMA Royalty stock and bought 6,217,869 units worth $44,091,555 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... und Bros. Advisors Lp667, L.P.B.... On average, XOMA Royalty executives and independent directors trade stock every 31 days with the average trade being worth of $3,397,377. The most recent stock trade was executed by Owen Hughes on 2 October 2023, trading 1,000 units of XOMA stock currently worth $13,830.
xoma has an extensive portfolio of products, programs, and technologies that are the subject of licenses the company has in place with other biotech and pharmaceutical companies. many of these licenses are the result of the company's pioneering efforts in the discovery and development of antibody therapeutics. there are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. in order to maximize its value in a licensing transaction, xoma continues to invest in x358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism. for more information, visit www.xoma.com.
XOMA Royalty executives and other stock owners filed with the SEC include: